Quinidine Induced Sicca Syndrome

Abstract

Two weeks after initiation of therapy with 1.2 gm/day quinidine sulphate, a 67 year old patient developed clinical and laboratory features of sicca syndrome. These subsided upon discontinuation of the treatment, but reappeared on a second challenge with this drug. Sicca syndrome represents a previously undescribed hypersensitivity reaction to quinidine.